Timothy Lee, MD
Interventional Cardiology · Birmingham, ALNPI 1477588408
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,500 of the $8,091 with a category attached, or 68.0%. Merck accounts for 71.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $5,738 and has fallen 96.6% since, to $193 in 2025.
Across 88 payments — averaging $91.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Medtronic$1K
- Novartis$264
- Johnson & Johnson$209
- Irhythm Technologies, Inc.$102
- Boston Scientific$100
- plus $442 from 15 others
What the payments were for
- Consulting fees$5,50068%
- Travel & lodging$79710%
- Food & beverage$1,79322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $5,762 |
| Medtronic(2 entities) | 16 | $1,213 |
| Novartis | 20 | $264 |
| Johnson & Johnson | 13 | $209 |
| Irhythm Technologies, Inc. | 5 | $102 |
| Boston Scientific | 1 | $100 |
| AstraZeneca | 6 | $79 |
| Penumbra, Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Abbott | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Abiomed | 1 | $23 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Philips North America LLC | 1 | $15 |
| Medicomp Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Celonova Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MK-2060$5,650
- HawkOne$623
- SYMPLICITY G3$111
- Ranger$100
How this compares
$8,091 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $64,250 |
| EntrestoSacubitril/Valsartan | 16 | $13,252 |
| Repatha SureclickEvolocumab | 13 | $9,494 |
| Atorvastatin Calcium | 132 | $1,385 |
| Losartan Potassium | 77 | $1,182 |
| Ezetimibe | 15 | $572 |
| Carvedilol | 69 | $552 |
| Amiodarone Hcl | 14 | $409 |
| Hydralazine Hcl | 40 | $357 |
| Amlodipine Besylate | 45 | $325 |
| Nitroglycerin | 12 | $294 |
| ClopidogrelClopidogrel Bisulfate | 19 | $282 |
| Olmesartan Medoxomil | 11 | $174 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $125 |
| Lisinopril | 14 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $64,25067 claims |
| NovartisEntresto | $264 | $13,25216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.